Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with cancer pain
Methadone may leads to higher participant‐reported pain intensity compared with morphine (low certainty).
1 finding from 1 review
Adverse events: appetite, thirst, somnolence · people with cancer pain
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain
1 finding from 1 review
Substantial benefit: At least 50% reduction in pain, or PGIC much improved · adults with chronic neuropathic pain
1 finding from 1 review
Lack of efficacy withdrawal · adults with chronic neuropathic pain
1 finding from 1 review
Withdrawals due to adverse events · adults with chronic neuropathic pain
1 finding from 1 review
Participants experiencing anyserious adverseevents · adults with chronic neuropathic pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Deaths · adults with chronic neuropathic pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
CI: Confidence interval · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rescue free laxation within 4 hours · patients with the management of opioid‐induced constipation in palliative care patients
Methylnaltrexone probably leads to higher rescue free laxation within 4 hours compared with placebo (moderate certainty).
1 finding from 1 review
Rescue free laxation within 24 hours · patients with the management of opioid‐induced constipation in palliative care patients
Methylnaltrexone probably leads to higher rescue free laxation within 24 hours compared with placebo (moderate certainty).
1 finding from 1 review
Participants with ≥ 1 vomiting episode · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in vomiting (≥1 episode) compared with placebo (low certainty).
1 finding from 1 review
Nausea · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in nausea (≥1 episode) compared with placebo (low certainty).
1 finding from 1 review
Adverse events · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of vomiting episodes · adults receiving intravenous opioids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nausea severity · adults receiving intravenous opioids
1 finding from 1 review
Use of rescue medication · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in rescue medication compared with placebo (low certainty).
1 finding from 1 review
Nausea · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
1 finding from 1 review
Number of vomiting episodes · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found